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In 2014/15 the United Kingdom experienced circulation 
of influenza A(H3N2) with impact in the elderly. Mid-
season vaccine effectiveness (VE) shows an adjusted 
VE of 3.4% (95% CI: −44.8 to 35.5) against primary 
care consultation with laboratory-confirmed influenza 
and −2.3% (95% CI: −56.2 to 33.0) for A(H3N2). The 
low VE reflects mismatch between circulating viruses 
and the 2014/15 northern hemisphere A(H3N2) vaccine 
strain. Early use of antivirals for prophylaxis and treat-
ment of vulnerable populations remains important.
We present the 2014/15 mid-season estimates of influ-
enza vaccine effectiveness (VE) for the United Kingdom 
of England, Wales, Scotland and Northern Ireland 
(UK). This season is dominated by early circulation of 
influenza A(H3N2) virus, and an overall VE in prevent-
ing medically attended laboratory-confirmed influenza 
in primary care of only 3.4% and against A(H3N2) of 
−2.3%. This report provides clear evidence of antigenic 
and genetic mismatch between circulating A(H3N2) 
viruses and the respective 2014/15 northern hemi-
sphere vaccine strain.
Background
The UK has a long-standing selective influenza immu-
nisation programme targeted at individuals at higher 
risk of severe disease, in particular all those 65 years 
and above and under 65-year olds in a clinical risk 
group, using inactivated trivalent influenza vaccine. 
The 2014/15 season is the second year where intrana-
sally administered live attenuated influenza vaccine 
(LAIV) has been offered to pre-school age children in 
the UK with certain areas also vaccinating children of 
school-age [1]. This winter has been characterised by 
early influenza activity, with A(H3N2) virus the domi-
nant circulating sub-type. In England, by week 4 2015 
peak influenza activity levels had exceeded those 
seen in the past three seasons, but not approached 
the peak levels seen in 2010/11 and 2008/09 [2]. The 
current season has led to large numbers of care home 
outbreaks, often in highly vaccinated populations, hos-
pitalisations and significant excess all-cause mortality 
in the over 65 year-old population.
The UK has well established methods to produce mid- 
and end-of-season estimates of VE in preventing pri-
mary care consultation due to laboratory-confirmed 
influenza infection [3,4]. The key aims of the present 
study were to provide early estimates of influenza VE 
in the UK to inform influenza prevention and control 
measures both for the remainder of this season and 
the forthcoming World Health Organization (WHO) con-
vened meeting at the end of February, where vaccine 
composition is decided for the forthcoming northern 
hemisphere 2015/16 season.
Study population and period
Data were derived from five primary care influenza 
sentinel swabbing surveillance schemes from England 
(two schemes), Scotland, Wales and Northern Ireland. 
Details of the Royal College of General Practitioners 
(RCGP), Public Health England (PHE) Specialist 
Microbiology Network (SMN), Public Health Wales, 
Public Health Agency (PHA) of Northern Ireland and 
Health Protection Scotland (HPS) swabbing schemes 
have been published previously [4].
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The study period ran from 1 October 2014 to 16 January 
2015. Patients were swabbed as part of clinical care, 
with verbal consent. Cases were defined as persons 
presenting during the study period in a participat-
ing general practitioner (GP) practice with an acute 
influenza-like-illness (ILI) who were swabbed and then 
tested positive for influenza A or B viruses. An ILI case 
was defined as an individual presenting in primary 
care with an acute respiratory illness with physician-
diagnosed fever or complaint of feverishness. Controls 
were individuals presenting with ILI in the same period 
that were swabbed and tested negative for influenza.
A standardised questionnaire was completed by the 
GP responsible for the patient during the consultation. 
Demographic, clinical and epidemiological information 
was collected from cases and controls, including date 
of birth, sex, pre-defined underlying clinical risk group, 
date of onset of respiratory illness, date of specimen 
collection, and influenza vaccination status for the 
2014/15 season, with vaccination dates and route of 
administration (injection/intranasal) and whether resi-
dent in an area where a primary school vaccination pro-
gramme was in operation.
Laboratory analysis
Laboratory confirmation was undertaken using compa-
rable methods with real-time polymerase chain reac-
tion (RT-PCR) assays capable of detecting circulating 
influenza A and influenza B viruses and other respira-
tory viruses [5,6]. Samples were sent to respective 
laboratories as previously described [4]. Further strain 
characterisation was also performed; influenza viruses 
were isolated in MDCK or MDCK-SIAT1 cells from RT-PCR 
positive samples from England as previously described 
[7,8]. Influenza A(H3N2) virus isolates with a haemag-
glutination titre ≥ 40 were characterised antigenically 
using post-infection ferret antisera in haemagglutina-
tion inhibition (HI) assays, with guinea pig red blood 
cells [9]. Nucleotide sequencing of the haemaggluti-
nin (HA) gene of a subset of influenza A(H3N2) viruses 
selected to be representative of the range of patient’s 
age, date of sample collection, geographical location, 
and antigenic characterisation of the influenza A(H3N2) 
virus isolate, if performed, was undertaken (primer 
sequences available on request), and phylogenetic 
trees were constructed with a neighbour-joining algo-
rithm available in the Mega 6 software (http://www.
megasoftware.net) [10]. HA sequences from reference 
strains used in the phylogenetic analysis were obtained 
from the EpiFlu database of the Global Initiative on 
Sharing Avian Influenza Data (GISAID) (Table 1).
Statistical analysis
Persons were defined as vaccinated if the date of vacci-
nation with the 2014/15 seasonal influenza vaccine was 
14 or more days before onset of illness. Those in whom 
the period between vaccination and onset of illness 
was less than 14 days were excluded, as were those 
where date of vaccination was missing. Those with a 
missing date of onset or an onset date more than seven 
days before the swab was taken were also excluded.
VE was estimated by the test negative case con-
trol (TNCC) design. In this design, VE is calculated 
as 1-(odds ratio) obtained using multivariable logis-
tic regression models with influenza PCR results and 
seasonal vaccination status as the linear predictor. 
VE was also estimated for influenza A only and for 
A(H3N2); Influenza A(H1N1) and B numbers were too 
small to examine. In the analyses evaluating VE for a 
specific type or strain, those positive for other types 
were excluded. Age (coded into four standard age 
groups, < 18, 18–44, 45–64 and ≥ 65 years), sex, clini-
cal risk group, surveillance scheme (RCGP, SMN, HPS, 
Wales, Northern Ireland), residence in an area where 
primary school age vaccination programme operated 
and date of onset (month) were investigated as poten-
tial confounding variables. All statistical analyses were 
carried out in Stata version 13 (StataCorp, College 
Station, Texas).
Results
A total of 2,278 individuals were swabbed in primary 
care during the study period and had a laboratory 
result available. The reasons for study inclusion and 
exclusion are outlined in Figure 1. Five persons were 
excluded because the influenza virus detected in them 
was a LAIV vaccine strain based either on sequence 
analysis or inferred based on influenza co-infection.
The details of the 1,341 individuals remaining in the 
study were stratified according to the swab result 
Figure 1
Flowchart showing specimen inclusion and exclusion 
criteria, interim 2014/15 influenza vaccine effectiveness 
evaluation, United Kingdom, week 40 2014 to week 3 2015
Total number of specimens in 
original dataset  
(N=2,278) 
Samples included in 
the analysis  
N=1,341  
Cases 
N=312  
Controls 
N=1,029  
(n=101)  
(n=6)  
(n=5)  
(n=80)  
(n=107)  
(n=67)  
(n=178)  
 
Sequentially excluded samples
Date of sample prior to 1 Oct 2014 (n=101)
Influenza status unknown  (n=6)
Live attenuated influenza vaccine strain (n=5)
Vaccination status unknown (n=80)
Date of vaccination not known (n=107)
Vaccination less than 14 days from illness onset  (n=67)
Date of illness onset unknown (n=178)
Swab more than seven days after illness onset (n=393)
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Table 1
Details for influenza A and B cases and controls, United Kingdom, week 40 2014 to week 3 2015 (1,029 controls and 312 
cases)
Controls Influenza B  cases
Influenza Aa  
cases
Influenza A(H1N1)
pdm09  
cases
Influenza A(H3N2) 
cases
P-valueb
(n = 1,029) (n = 16) (n = 296) (n = 14) (n = 271)
n (%) n (%) n (%) n (%) n (%)
Age group (years)
< 18 269(79.8) 3(0.9) 65(19.3) 2(0.6) 60(17.8)
0.40
18–44 412(76.7) 7(1.3) 118(22) 6(1.1) 106(19.7)
45–64 244(74.8) 5(1.5) 77(23.6) 6(1.8) 69(21.2)
65 + 104(74.3) 1(0.7) 35(25) 0(0) 35(25)
Missing information 0(0) 0(0) 1(100) 0(0) 1(100)
Sex
Female 592(77.2) 8(1) 167(21.8) 9(1.2) 153(19.9)
0.71Male 432(76.3) 8(1.4) 126(22.3) 5(0.9) 115(20.3)
Missing information 5(62.5) 0(0) 3(37.5) 0(0) 3(37.5)
Scheme
Northern Ireland 29(87.9) 1(3) 3(9.1) 0(0) 3(9.1)
<0.001
RCGP (England) 374(67) 6(1.1) 178(31.9) 10(1.8) 168(30.1)
SMN (England) 138(77.1) 2(1.1) 39(21.8) 2(1.1) 32(17.9)
Scotland 466(87.6) 7(1.3) 59(11.1) 2(0.4) 51(9.6)
Wales 22(56.4) 0(0) 17(43.6) 0(0) 17(43.6)
Risk group
No 710(76.5) 15(1.6) 203(21.9) 10(1.1) 188(20.3)
0.93Yes 215(76.2) 0(0) 67(23.8) 1(0.4) 63(22.3)
Missing information 104(79.4) 1(0.8) 26(19.8) 3(2.3) 20(15.3)
Interval onset to swab (days)
0–1 140(69.7) 1(0.5) 60(29.9) 2(1) 56(27.9)
<0.0012–4 498(74) 10(1.5) 165(24.5) 8(1.2) 149(22.1)
5–7 391(83.7) 5(1.1) 71(15.2) 4(0.9) 66(14.1)
Vaccination status and route
Unvaccinated 852(77.5) 15(1.4) 232(21.1) 13(1.2) 210(19.1)
0.14c
Vaccinated 177(73.1) 1(0.4) 64(26.4) 11(4.5) 61(25.2)
Injection 138(72.6) 1(0.5) 51(26.8) 0(0) 49(25.8)
Intranasal 23(79.3) 0(0) 6(20.7) 1(3.4) 5(17.2)
Missing route 16(69.6) 0(0) 7(30.4) 0(0) 7(30.4)
Primary school age vaccination programme
No 289(67.5) 4(0.9) 135(31.5) 10(2.3) 121(28.3)
<0.001Yes 726(81.3) 12(1.3) 155(17.4) 4(0.4) 144(16.1)
Missing information 14(70) 0(0) 6(30) 0(0) 6(30)
Month of event
Oct 2014 217(95.6) 3(1.3) 7(3.1) 1(0.4) 5(2.2)
<0.001
Nov 2014 343(94.2) 6(1.6) 15(4.1) 0(0) 15(4.1)
Dec 2014 375(64.1) 4(0.7) 207(35.4) 6(1) 195(33.3)
Jan 2015 94(57.3) 3(1.8) 67(40.9) 6(3.7) 56(34.1)
RCGP: Royal College of General Practitioners’ surveillance scheme; SMN: Specialist Microbiology Network.
a There were 11 cases of influenza A infection where the subtype was unknown.
b Controls vs any influenza case.
c Vaccinated vs unvaccinated.
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(Table 1). Positivity rates differed significantly by 
month, scheme and primary school age vaccination 
programme area.
Influenza A(H3N2) strain characterisation
During the study period, a total of 127 A(H3N2) circulat-
ing viruses were isolated from all referred clinical sam-
ples and antigenically characterised by HI analysis. The 
majority of A(H3N2) viruses analysed (100/127; 79%) 
were antigenically similar to the A(H3N2) virus com-
ponent of the 2014/15 northern hemisphere vaccine 
A/Texas/50/2012 (≤ 4-fold difference) with antiserum 
raised against A/Texas/50/2012 in antigenic character-
isation by HI); however a proportion of A(H3N2) viruses 
(21%) showed reduced reactivity (> 4-fold difference) 
(Table 2).
These viruses were antigenically similar to A/
Switzerland/9715293/2013, the recommended A(H3N2) 
component of the 2015 southern hemisphere vaccine. 
A > 4-fold difference in HI assay titres with reference 
antiserum is considered to be significant antigenic 
drift. Of the 44 UK influenza A(H3N2) viruses ana-
lysed to date by sequencing, the HA genes of these 
viruses belonged in the genetic clade 3C, as does the 
2014/15 A(H3N2) vaccine strain A/Texas/50/2012 and 
A/Switzerland/9715293/2013, one of the three recom-
mended strains for the  southern hemisphere 2015 
vaccine composition. However, the majority (35/44; 
79.5%) of the HA sequences of 2014/15 UK viruses 
analysed were further characterised within this clade 
to belong in subgroup 3C.2a of group 3C.2, with fewer 
(9/44 17.3%) in group 3C.3 (Figure 2). These groups are 
considered genetically distinct from the 2014/15 A/
Texas/50/2012(H3N2)-like clade 3C.1 vaccine reference 
strain.
Model fitting for vaccine effectiveness 
estimation
When estimating vaccine effectiveness, age group, 
sex, month of onset, surveillance scheme and primary 
school age programme area were adjusted for in a 
multivariable logistic regression model. Only surveil-
lance scheme, time period and primary school age 
programme area were significantly associated with 
having a positive swab, and all were confounders for 
vaccine effectiveness (changing the estimate by more 
than 5%). Information on risk group was missing for 131 
samples (9.8%) and was therefore not included in the 
final model. If risk group was included, it was found 
not to be associated with being positive and the VE 
estimates remained similar.
Table 3 shows vaccine effectiveness estimates against 
all influenza, influenza A and influenza A(H3N2). There 
were inadequate samples to enable estimation of 
effectiveness against influenza A(H1N1)pdm09 or influ-
enza B. The adjusted VE of influenza vaccine against all 
influenza was 3.4% and was very similar for A(H3N2), 
reflecting the fact that A(H3N2) is the dominant circu-
lating virus strain this season.
Discussion
This paper presents the mid-season estimates of influ-
enza vaccine effectiveness for the UK. In a season 
dominated by early circulation of influenza A(H3N2) 
virus, we found the overall VE in preventing medically 
attended laboratory-confirmed influenza in primary 
care was only 3.4% and −2.3% specifically against 
A(H3N2). We also found clear evidence of antigenic and 
genetic mismatch between circulating A(H3N2) viruses 
and the 2014/15 northern hemisphere vaccine strain.
The UK, together with other European countries, the 
United States, Canada and Australia has well estab-
lished systems to generate interim estimates of sea-
sonal influenza VE. These early results are used to 
optimise in-season control and prevention measures, 
to inform other countries where the influenza sea-
son may have just started or is about to start, and to 
contribute to forthcoming WHO vaccine composition 
deliberations.
The UK, as observed in North America and some other 
European countries [11,12] has experienced a season 
dominated by early circulation of influenza A(H3N2) 
virus – with clear evidence of emergence of a drifted 
A(H3N2) strain, first seen in North America in spring 
2014 [11], and then in Australia in mid-2014 [13]. This 
drifted strain has reduced antigenic reactivity with 
antiserum raised to the current A(H3N2) vaccine strain 
(A/Texas/50/2012), and is antigenically more closely 
related to A/Switzerland/9715293/2013, the A(H3N2) 
virus selected as one of the three recommended com-
ponents for the 2015 southern hemisphere influenza 
vaccine [14].
Characterisation of circulating influenza viruses 
involves both genetic and antigenic characterisation. 
Genetic analysis focusses on detailed comparison of 
the HA genes of viruses, tracking changes over time 
and linking this to phylogenetic analysis of sequence 
clustering to determine emerging virus groups and 
changes in receptor binding and other important anti-
genic epitopes. Genetic variation does not always 
correlate with antigenic variation. The interpretation 
of both data sources is complex, as not all viruses 
Table 2
Influenza A(H3N2) viruses isolated from specimens 
with < 4-fold, 4-fold, or > 4-fold difference in 
haemagglutination inhibition (HI) assay titres compared 
with A/Texas/50/2012, the 2014/15 northern hemisphere 
influenza seasonal A(H3N2) influenza vaccine component, 
United Kingdom, week 40 2014 to week 3 2015 (n = 127)
Influenza 
virus
Change in reactivity with A/Texas/50/2012 
antiserum
<4-fold 4-fold >4-fold Total
N (%) n (%) N (%) n (%)
A(H3N2) 65 51.2 35 27.6 27 21.3 127 100
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 A/England/44840069/2014 
 A/England/44940038/2014  
 A/England/529/2014  
 A/England/44840067/2014  
 A/England/44780079/2014  
 A/Scotland/426161/2014 
 A/England/44160198/2014  
 A/England/44160199/2014 
 A/England/511/2014  
 A/England/44160201/2014 
 A/England/44160202/2014  
 A/England/512/2014  
 A/England/507/2014 
 A/England/43020765/2014 
 A/England/45040065/2014  
 A/England/45000006/2014 
 A/England/45100196/2014 
 A/England/44860850/2014 
 A/England/44020584/2014 
 A/England/44060047/2014 
 A/England/44320794/2014 
 A/Scotland/426901/2014 
 A/England/44320795/2014  
 A/England/44840003/2014  
 A/England/45040069/2014  
 A/Scotland/426752/2014 
 A/England/44760132/2014 
 A/England/525/2014  
 A/England/45060041/2014  
 A/England/45000008/2014  
 A/England/45080158/2014  
 A/Scotland/426918/2014 
 A/England/45000028/2014  
 A/England/44540273/2014  
 A/England/43400390/2014 
 A/England/45000010/2014  
 A/England/43320581/2014 
 A/England/43860187/2014 
 A/England/45060049/2014  
 A/England/44080181/2014  
 A/HongKong/5738/2014 
 A/England/43700330/2014 
 A/England/671/2013 
 A/England/370/2014 
 A/England/40180189/2014 
 A/England/41180423/2014 
 A/England/35120047/2013 
 A/Norway/1903/2014 
 A/Switzerland/9715293/2014 
 A/England/43460207/2014 
 A/England/479/2014 
 A/Samara/73/2013 
 A/England/44640016/2014  
 A/England/41860057/2014 
 A/England/498/2014 
 A/England/34560054/2013 
 A/England/41500098/2014 
 A/England/40280202/2014 
 A/England/420/2014 
 A/England/41800221/2014 
 A/England/41420344/2014 
 A/England/2/2014 
 A/Scotland/425954/2014 
 A/England/513/2014  
 A/England/43920370/2014 
 A/England/298/2014 
 A/England/34500001/2013 
 A/England/43860188/2014 
 A/England/41420350/2014 
 A/Scotland/426685/2014 
 A/England/44320793/2014  
 A/England/41060123/2014 
 A/England/655/2013 
 A/England/41800219/2014 
 A/England/516/2014  
 A/England/45000025/2014  
 A/England/533/2014 
 A/England/534/2014 
 A/England/536/2014  
 A/Texas/50/2012 
 A/Victoria/361/2011 
 A/Athens GR11/22012 
 A/Stockholm/18/2011 
 A/Perth/16/2009 
0.002 
3A 
3B 
3C.1 
3C 
3C.2 
3C.3 
3C.2a 
3C.3a 
Figure 2
Phylogenetic analysis with sequences of the HA1 subunit of the haemagglutinin (HA) gene from reference viruses 
downloaded from the GISAID EpiFlu database and influenza A(H3N2) sequences derived from patients in the United 
Kingdom, week 40 2014 to week 3 2015 
GISAID: Global Initiative on Sharing Avian Influenza Data.
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can be cultivated in sufficient quantity for antigenic 
characterisation, so that viruses for which sequence 
information is available may not be antigenically 
characterised, leading to potential bias in interpreta-
tion. This is particularly relevant to the discussion of 
antigenic characterisation data for A(H3N2) viruses in 
the 2014/15 winter season. Some circulating A(H3N2) 
viruses are difficult to grow in tissue culture as a result 
of genetic drift affecting receptor binding properties 
[15], and viruses grown in eggs may have egg adap-
tive changes which make the analysis of antigenic drift 
complex. Most A(H3N2) strains seen since February 
2014 fell into the HA genetic clade (3C) for which A/
Switzerland/9715293/2013 was a prototype represent-
ative strain. Antigenic and genetic characterisation 
data indicate that A/Switzerland/9715293/2013-like 
strains have circulated in the UK during winter 2014/15. 
There is a clear antigenic mismatch between the north-
ern hemisphere H3N2 vaccine strain and the circulating 
variant in winter of 2014/15. The full picture of viro-
logical variation requires further detailed analysis, not 
possible at this stage of the 2014/15 season.
Our observation of an absence of significant effec-
tiveness in preventing medically-attended laboratory-
confirmed influenza in primary care due to A(H3N2) are 
congruent with the findings recently reported from the 
US [16] who report low effectiveness of 22% (95% con-
fidence interval (CI): 5–35) and from Canada who report 
a VE of −8% (95% CI: −50 to 23) against laboratory-
confirmed, medically-attended influenza A(H3N2) virus 
infection in primary care [17]. The observation of low 
or non-significant effectiveness in 2014/15 in the UK 
and in North America correlates with the direct mis-
match seen between the vaccine virus and A(H3N2) 
strains circulating this winter. Vaccine mismatch due to 
circulation of drifted strains does occasionally occur, 
although this is the lowest estimate of influenza VE 
reported by the UK over the past decade using the 
TNCC approach to measure VE [3,4]. It is also impor-
tant to highlight the uncertainty of our estimate. The 
upper 95% CI of 35% shows we can be confident that 
VE is low at this point although we cannot be clear that 
influenza vaccine has no effectiveness this season. 
Indeed the significantly lower influenza positivity in 
areas where children of school age were vaccinated 
compared to non-pilot areas (Table 1) is suggestive of 
a possible impact of the childhood influenza vaccina-
tion programme. Furthermore, this mid-season analy-
sis does not preclude the likelihood that the vaccine 
should offer protection from different types of influ-
enza, such as influenza B that may still circulate later 
in the season. All these elements will form part of the 
end-of-season analysis including stratification by age-
group and scheme.
The WHO has made their recommendations for the com-
position of the influenza vaccine for the 2015 southern 
hemisphere winter in September 2014, including a 
switch to a A/Switzerland/9715293/2013 (H3N2)-like 
virus [18]. The WHO influenza vaccine composition 
group will convene shortly, at the end of February 
2015, to consider recommendations for the forthcoming 
northern hemisphere 2015/16 winter, and the findings 
in this paper will contribute to their deliberations. The 
observation of low vaccine effectiveness this season 
highlights the vital importance of implementing other 
prevention and control measures for the remainder of 
this season, in particular the early use of influenza 
antivirals for post-exposure prophylaxis and treatment 
of vulnerable populations, such as the elderly, together 
with appropriate infection control measures.
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Table 3
Samples positive (cases) and negative (controls) for influenza according to vaccination status and vaccine effectiveness 
estimates, United Kingdom, week 40 2014 to week 3 2015  
Cases 
(vaccinated : 
unvaccinated)
Controls 
(vaccinated : 
unvaccinated)
Crude VE
(95% CI)
Adjusteda VE
(95% CI)
All influenza (A and B) 65 : 247
177 : 825
−26.7% (−74.0 to 7.8) 3.4% (−44.8 to 35.5)
All influenza A 64 : 232 −32.2% (−82.2 to 4.0) −0.7% (−52.0 to 33.2)
Influenza A(H3N2) only 61 : 210 −39.8% (−94.1 to −0.7) −2.3% (−56.2 to 33.0)
CI: confidence interval; VE: vaccine effectiveness.
a Adjusted for age group, sex, month, surveillance scheme and primary school area.
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